Last reviewed 2026-04-20 · How we verify

AMG 133

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nausea
• Vomiting
• Decreased appetite
• Headache
• Abdominal pain
• Gastrooesophageal reflux disease
• Gastroenteritis viral
• Myalgia
• Dizziness
• Conjunctival haemorrhage
• Eye pain
• Abdominal pain upper

Key clinical trials

• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity (PHASE3)
• A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations (PHASE1)
• A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight (PHASE2)
• A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function (PHASE1)
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy (PHASE3)
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy (PHASE3)
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (PHASE3)
• The Effect of AMG 133 on Gastric Emptying (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AMG 133 CI brief — competitive landscape report
• AMG 133 updates RSS · CI watch RSS
• Amgen portfolio CI